IRVING, Texas, Nov. 1 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7th, at 2:00 pm Eastern Time at the New York Palace Hotel.
The presentation will cover three key platform technologies in the areas of drug delivery and vaccine adjuvants, and will also provide information on the Company and the development status of its lead product candidate.
DelSite specializes in the development of novel liquid and powder formulations for protein/peptide therapeutics and vaccines using its proprietary platform technologies. So far this year, DelSite has signed six technology rights evaluation agreements with commercial partners and institutions that are interested in its delivery technology.
About Rodman & Renshaw, LLC
Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. It also provides research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital-intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,
biopharmaceutical and consumer products company currently utilizing
naturally-occurring complex carbohydrates to manufacture and market
products for mucositis, radiation dermatitis, wound and oral care, as well
as to manufacture and market the nutraceutical raw material Manapol(R) and
cosmetic raw material Hydrapol(TM). Carrington
|SOURCE Carrington Laboratories, Inc.|
Copyright©2007 PR Newswire.
All rights reserved